+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Rate of elimination of tracer doses of phenytoin at different steady-state serum phenytoin concentrations in epileptic patients



Rate of elimination of tracer doses of phenytoin at different steady-state serum phenytoin concentrations in epileptic patients



British Journal of Clinical Pharmacology 1(2): 155-161



1 Serum phenytoin concentration, the serum half-life of a tracer dose of carbon-labelled phenytoin, and the ratio of the major metabolite of phenytoin to unchanged drug in urine (p-HPPH: DPH ratio) were measured in epileptic patients on chronic anticonvulsant therapy. 2 A significant correlation was found between serum phenytoin concentration and half-life, the slope of the regression line being dose dependent. 3 A significant negative correlation was found between serum phenytoin concentration and p-HPPH: DPH ratio. 4 Increasing the daily dose of phenytoin lead to a lengthening of the half-life and a reduction in the p-HPPH: DPH ratio. The reverse occurred on lowering the dose. 5 These changes indicate that phenytoin hydroxylation is saturable. 6 Difficulty in achieving a stable serum phenytoin concentration within the therapeutic range may result.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055372007

Download citation: RISBibTeXText

PMID: 22454903

DOI: 10.1111/j.1365-2125.1974.tb00225.x


Related references

Steady-state serum phenytoin concentrations after nasogastric tube administration of immediate-release phenytoin tablets and extended-release phenytoin capsules: an open-label, crossover, clinical trial. Current Therapeutic Research Clinical and Experimental 68(5): 325-337, 2007

Changes in serum phenytoin concentrations in epileptic patients produced by changing phenytoin preparation from granular form to a novel 10% powder. Epilepsia 41(Suppl. 9): 66, 2000

Comparison of saliva and serum unbound phenytoin concentrations in patients receiving phenytoin monotherapy versus concomitant phenytoin/valproic acid. Epilepsia 41(Suppl. 7): 118, 2000

Steady state serum phenytoin levels in indian epileptic population. Journal of Neurology 232(Suppl.): 281, 1985

Effect of increased bioavailability of phenytoin tablets on serum phenytoin concentration in epileptic out-patients. British Journal of Clinical Pharmacology 8(1): 37-41, 1979

Comparison of serum phenytoin levels in epileptic patients who swallowed their phenytoin tablets with or without previous chewing. European Journal of Clinical Pharmacology 14(3): 191-194, 1978

Plasma and saliva concentrations of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in relation to the incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients. Journal of Periodontology 67(6): 597-602, 1996

The effect of sucralfate on the steady-state serum concentrations of phenytoin. Drug Metabolism and Drug Interactions 7(4): 287-293, 1989

Phenytoin bioavailability assessed by steady state serum concentrations. Israel Journal of Medical Sciences 21(4): 327-330, 1985

Covariance analysis of laboratory variance in steady-state serum phenytoin concentrations. Clinical Pharmacokinetics 20(4): 331-335, 1991

The steady-state pharmacokinetics of phenytoin and topiramate in epileptic patients on monotherapy, and during combination therapy. Epilepsia 35(Suppl. 8): 54, 1994

Effect of ciprofloxacin on serum phenytoin concentrations in epileptic patients. Pharmacotherapy 11(3): 275, 1991

Rate of decline of serum phenytoin concentration following phenytoin intoxication in hospitalized patients. Drug Intelligence & Clinical Pharmacy 16(6): 473-474, 1982

Rapid and slow release phenytoin in epileptic patients at steady state: comparative plasma levels and toxicity. Journal of Pharmacokinetics and Biopharmaceutics 10(4): 365-382, 1982

Pharmacological influence of valproate on phenobarbitone and phenytoin serum concentrations in epileptic patients. Der Nervenarzt 50(11): 743-746, 1979